(VIANEWS) – AIRBUS (AIR.PA), MONTEA (MONT.BR), SARTORIUS STED BIO (DIM.PA) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. AIRBUS (AIR.PA)
30.3% sales growth and 35.7% return on equity
Airbus SE, together with its subsidiaries, engages in the design, manufacture, and delivery of aerospace products, services, and solutions worldwide. It operates through three segments: Airbus, Airbus Helicopters, and Airbus Defence and Space. The Airbus segment develops, manufactures, markets, and sells commercial jet passenger aircraft, freighter aircraft, regional turboprop aircraft, and aircraft components, as well as provides aircraft conversion and related services. The Airbus Helicopters segment develops, manufactures, markets, and sells civil and military helicopters; and provides helicopter-related services. The Airbus Defence and Space segment designs, develops, delivers, and supports military air systems and related services. This segment also offers civil and defence space systems for telecommunications, earth observations, navigation, and science and orbital systems; missile and space launcher systems; and services around data processing from platforms, secure communication, and cyber security. The company was formerly known as Airbus Group SE and changed its name to Airbus SE in April 2017. Airbus SE was incorporated in 1998 and is headquartered in Leiden, the Netherlands.
Earnings Per Share
As for profitability, AIRBUS has a trailing twelve months EPS of €4.96.
PE Ratio
AIRBUS has a trailing twelve months price to earnings ratio of 32.68. Meaning, the purchaser of the share is investing €32.68 for every euro of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 35.7%.
Volume
Today’s last reported volume for AIRBUS is 145676 which is 84.05% below its average volume of 913674.
Dividend Yield
As claimed by Morningstar, Inc., the next dividend payment is on Apr 25, 2023, the estimated forward annual dividend rate is 1.8 and the estimated forward annual dividend yield is 1.29%.
Sales Growth
AIRBUS’s sales growth is 7.7% for the current quarter and 30.3% for the next.
More news about AIRBUS.
2. MONTEA (MONT.BR)
13.9% sales growth and 8.42% return on equity
Montea NV is a public regulated real estate company under Belgian law (GVV/SIR) that specializes in logistics real estate in Belgium, the Netherlands, France, and Germany. The company is a benchmark player in this market. Montea literally offers its customers the space to grow through versatile and innovative property solutions. In this way, Montea creates value for its shareholders. As of 31/12/2023 the property portfolio represented a total surface of 1,959,242 m², spread across 95 locations. Montea NV has been listed on Euronext Brussels (MONT) and Euronext Paris (MONTP) since the end of 2006.
Earnings Per Share
As for profitability, MONTEA has a trailing twelve months EPS of €6.44.
PE Ratio
MONTEA has a trailing twelve months price to earnings ratio of 13.35. Meaning, the purchaser of the share is investing €13.35 for every euro of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 8.42%.
Volume
Today’s last reported volume for MONTEA is 4303 which is 80.76% below its average volume of 22375.
Dividend Yield
According to Morningstar, Inc., the next dividend payment is on May 19, 2023, the estimated forward annual dividend rate is 3.3 and the estimated forward annual dividend yield is 4.03%.
More news about MONTEA.
3. SARTORIUS STED BIO (DIM.PA)
12.2% sales growth and 8.15% return on equity
Sartorius Stedim Biotech S.A. engages in the production and sale of instruments and consumables for the biopharmaceutical industry worldwide. The company offers various products, such as cell lines; cell culture media; bioreactors; advanced therapies; and a range of products for separation, purification, and concentration processes, as well as products and systems for storage and transportation of intermediate and finished biological products. It also provides cell cultivation, fermentation, separation, purification, and fluid management services; biolayer interferometry instruments; microbiology enumeration, sterility testing, and air monitoring instruments; pipette products; sensors and analyzers; biomolecule analysis tools; flow cytometry; batch and intensified chromatography systems; lab data and fleet management software; live cell imaging and analysis; surface plasmon resonance solutions; and weighing products. In addition, the company offers data analytics software for modeling and optimizing processes of biopharmaceutical development and production; process automation platform and software; and develops and produces transfection, as well as other DNA/RNA delivery reagents and plasmid DNA. It serves manufacturers of medications, vaccines, foods, and chemicals, as well as research and development laboratories. The company was incorporated in 1978 and is headquartered in Aubagne, France. As of December 31, 2023, Sartorius Stedim Biotech S.A. operates as a subsidiary of Sartorius AG.
Earnings Per Share
As for profitability, SARTORIUS STED BIO has a trailing twelve months EPS of €3.36.
PE Ratio
SARTORIUS STED BIO has a trailing twelve months price to earnings ratio of 78.66. Meaning, the purchaser of the share is investing €78.66 for every euro of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 8.15%.
Revenue Growth
Year-on-year quarterly revenue growth declined by 8.2%, now sitting on 2.72B for the twelve trailing months.
Moving Average
SARTORIUS STED BIO’s value is above its 50-day moving average of €248.51 and way higher than its 200-day moving average of €234.18.
Sales Growth
SARTORIUS STED BIO’s sales growth for the next quarter is 12.2%.
More news about SARTORIUS STED BIO.
4. VISTIN PHARMA (VISTN.OL)
6.6% sales growth and 19.84% return on equity
Vistin Pharma ASA, through its subsidiary, Vistin Pharma AS, produces and sells active pharmaceutical ingredients (APIs) worldwide. It offers metformin HCl APIs and direct compressive granulates for the pharmaceutical industry. Vistin Pharma ASA was founded in 1969 and is headquartered in Oslo, Norway.
Earnings Per Share
As for profitability, VISTIN PHARMA has a trailing twelve months EPS of kr1.27.
PE Ratio
VISTIN PHARMA has a trailing twelve months price to earnings ratio of 17.87. Meaning, the purchaser of the share is investing kr17.87 for every norwegian krone of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 19.84%.
Dividend Yield
As maintained by Morningstar, Inc., the next dividend payment is on Jun 5, 2024, the estimated forward annual dividend rate is 1.25 and the estimated forward annual dividend yield is 5.36%.
Yearly Top and Bottom Value
VISTIN PHARMA’s stock is valued at kr22.70 at 07:20 EST, under its 52-week high of kr25.10 and way higher than its 52-week low of kr20.60.
Sales Growth
VISTIN PHARMA’s sales growth is 10.6% for the current quarter and 6.6% for the next.
Moving Average
VISTIN PHARMA’s worth is under its 50-day moving average of kr23.01 and below its 200-day moving average of kr23.04.
More news about VISTIN PHARMA.
